Table 1.

Participant demographic and baseline characteristics

	n=17
Age, median (range)	57.9 (34-90)
Sex, n (%)
Female	17 (100)
Race, n (%)
Caucasian	14 (82)
Asian	2 (12)
Unknown	1 (6)
Stage at Diagnosis, n (%)
I	3 (18)
II	9 (53)
III	4 (24)
IV	1 (6)
Sites of Metastatic Disease, n (%)
Visceral	12 (71)
No visceral disease	5 (29)
Median lines prior therapy# (range)	2 (0-6)
Median number of treatment cycles on study (range)	3 (1-8)

^#In metastatic setting. Adjuvant therapy excluded.